Class III Antiarrhythmics: Potassium Channel Blockers

Class III antiarrhythmics block the repolarizing potassium currents of the cardiac action potential. By inhibiting potassium efflux during repolarization they prolong the action-potential duration and the effective refractory period, which can interrupt and prevent re-entrant arrhythmias. Because they lengthen repolarization, several class III agents also carry a risk of QT prolongation and torsades de pointes.

Definition

Class III antiarrhythmics are agents that block cardiac repolarizing potassium currents, prolonging the action-potential duration and the effective refractory period to suppress re-entrant arrhythmias.

Scope

The entry covers the electrophysiology of repolarizing potassium current block, the resulting prolongation of refractoriness, the concept of reverse use dependence, and the class-defining tension between antiarrhythmic efficacy and QT-related proarrhythmia. It notes that amiodarone is a multichannel agent often grouped here despite acting across several Vaughan Williams classes. It is a reference topic and provides no dosing or treatment instructions.

Key concepts

• Repolarizing potassium currents (e.g. the rapid delayed rectifier)
• Action-potential and refractory-period prolongation
• Interruption of re-entry
• Reverse use dependence
• QT prolongation and torsades de pointes
• Amiodarone as a multichannel agent

Mechanisms

Class III agents inhibit outward potassium currents responsible for phase-3 repolarization, prolonging the plateau and the overall action-potential duration; the lengthened effective refractory period makes re-entry harder to sustain. Many pure class III agents show reverse use dependence, meaning their action-potential-prolonging effect is greater at slow heart rates — which both limits efficacy during tachycardia and raises proarrhythmic risk at rest. Amiodarone, though conventionally placed in class III for its prominent potassium-channel block, also blocks sodium and calcium channels and antagonizes adrenergic receptors, making it a multichannel agent that the Sicilian Gambit and modernized classifications describe by its full target profile.

Clinical relevance

Class III agents are used in rhythm-control strategies for atrial and ventricular arrhythmias, and amiodarone in particular is a widely studied multichannel agent. Their defining caution is QT prolongation and the risk of torsades de pointes, which shapes how the class is appraised. This entry describes mechanisms and trial evidence for reference and is not a basis for individual prescribing decisions.

Evidence & guidelines

In the SCD-HeFT trial, amiodarone did not reduce mortality compared with placebo in heart failure, whereas an implantable defibrillator did, illustrating that class III pharmacotherapy is not a universal substitute for device therapy in preventing sudden death. Ventricular-arrhythmia guidance, such as the 2015 ESC guidelines, situates class III agents within rhythm management while accounting for their proarrhythmic potential.

History

Action-potential prolongation was recognized as a distinct antiarrhythmic mechanism and designated class III in the Vaughan Williams scheme, with amiodarone and sotalol as prominent examples. The recognition of QT-related proarrhythmia and reverse use dependence refined understanding of the class, and the Sicilian Gambit and 2018 modernized classification clarified that agents like amiodarone act across multiple targets.

Debates

Should amiodarone be classed as a class III agent at all?

Amiodarone blocks potassium, sodium and calcium currents and antagonizes adrenergic receptors, so labelling it purely class III understates its pharmacology; mechanism-and-target frameworks argue for describing it by its full multichannel profile.

Key figures

• Bramah N. Singh
• Miles Vaughan Williams

Seminal works

• bardy-2005
• vaughan-williams-sicilian-1991
• lei-2018

Frequently asked questions

Why do class III antiarrhythmics carry a risk of torsades de pointes?

By blocking repolarizing potassium currents they prolong the action potential and the QT interval; excessive prolongation, especially at slow heart rates because of reverse use dependence, can trigger the polymorphic ventricular tachycardia known as torsades de pointes.

Why is amiodarone described as a multichannel drug?

Although grouped with class III for its potassium-channel block, amiodarone also blocks sodium and calcium channels and antagonizes beta-adrenergic receptors, so its actions span several Vaughan Williams classes rather than one.